CoChat
Sign Up
Cited by 533

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

PCSK9: a convertase that coordinates LDL catabolism

Horton, Jay D., Cohen, Jonathan C., Hobbs, Helen H.·2009·Journal of Lipid Research
DOI 10.1194/jlr.r800091-jlr200
Open this paper in CoChat — free account

Abstract

The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD). PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for degradation. Individuals with loss-of-function mutations in PCSK9 have reduced plasma levels of LDL cholesterol and are protected from CHD; these observations have validated PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention of CHD.

Overview

Integrity signals

Registry

Crossref · 10.1194/jlr.r800091-jlr200

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161 · DOI · Paper page
  2. Zaid, 2008, Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration, Hepatology., 48, 646, 10.1002/hep.22354 · DOI · Paper page
  3. Horton, 2007, Molecular biology of PCSK9: its role in LDL metabolism, Trends Biochem. Sci., 32, 71, 10.1016/j.tibs.2006.12.008 · DOI · Paper page
  4. Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc. Natl. Acad. Sci. USA., 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
  5. Dewpura, 2008, PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans, FEBS J., 275, 3480, 10.1111/j.1742-4658.2008.06495.x · DOI
  6. Benjannet, 2006, The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications, J. Biol. Chem., 281, 30561, 10.1074/jbc.M606495200 · DOI · Paper page
  7. Mayne, 2008, Plasma PCSK9 levels are significantly modified by statins and fibrates in humans, Lipids Health Dis., 7, 22, 10.1186/1476-511X-7-22 · DOI
  8. Careskey, 2008, Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9, J. Lipid Res., 49, 394, 10.1194/jlr.M700437-JLR200 · DOI
  9. Lambert, 2008, Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment, Clin. Chem., 54, 1038, 10.1373/clinchem.2007.099747 · DOI
  10. Grefhorst, 2008, Plasma PCSK9 preferentially reduces liver LDL receptors in mice, J. Lipid Res., 49, 1303, 10.1194/jlr.M800027-JLR200 · DOI · Paper page
  11. Maxwell, 2005, Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment, Proc. Natl. Acad. Sci. USA., 102, 2069, 10.1073/pnas.0409736102 · DOI · Paper page
  12. Schmidt, 2008, Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo, Biochem. Biophys. Res. Commun., 370, 634, 10.1016/j.bbrc.2008.04.004 · DOI
  13. Brown, 2008, Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL, J. Lipid Res., S15
  14. Jeong, 2008, Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2, J. Lipid Res., 49, 399, 10.1194/jlr.M700443-JLR200 · DOI · Paper page
  15. Costet, 2006, Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c, J. Biol. Chem., 281, 6211, 10.1074/jbc.M508582200 · DOI
  16. Langhi, 2008, Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes, FEBS Lett., 582, 949, 10.1016/j.febslet.2008.02.038 · DOI
  17. Kourimate, 2008, Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9, J. Biol. Chem., 283, 9666, 10.1074/jbc.M705831200 · DOI
  18. Rudenko, 2002, Structure of the LDL receptor extracellular domain at endosomal pH, Science., 298, 2353, 10.1126/science.1078124 · DOI · Paper page
  19. Zhang, 2007, Binding of proprotein convertase subtilisin/kexin yype 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, J. Biol. Chem., 282, 18602, 10.1074/jbc.M702027200 · DOI · Paper page
  20. Zhang, 2008, Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor, Proc. Natl. Acad. Sci. USA., 105, 13045, 10.1073/pnas.0806312105 · DOI · Paper page
  21. Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat. Struct. Mol. Biol., 14, 413, 10.1038/nsmb1235 · DOI · Paper page
  22. Fisher, 2007, Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation, J. Biol. Chem., 282, 20502, 10.1074/jbc.M701634200 · DOI · Paper page
  23. Hampton, 2007, The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain, Proc. Natl. Acad. Sci. USA., 104, 14604, 10.1073/pnas.0703402104 · DOI
  24. Piper, 2007, The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol, Structure., 15, 545, 10.1016/j.str.2007.04.004 · DOI · Paper page
  25. Kwon, 2008, Molecular basis for LDL receptor recognition by PCSK9, Proc. Natl. Acad. Sci. USA., 105, 1820, 10.1073/pnas.0712064105 · DOI · Paper page
  26. McNutt, 2007, Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells, J. Biol. Chem., 282, 20799, 10.1074/jbc.C700095200 · DOI · Paper page
  27. Humphries, 2006, Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk, J. Med. Genet., 43, 943, 10.1136/jmg.2006.038356 · DOI · Paper page
  28. Bottomley, 2009, Structural and biochemical characterization of the wild type PCSK9/EGF(AB) complex and natural familial hypercholesterolemia mutants, J. Biol. Chem., 284, 1313, 10.1074/jbc.M808363200 · DOI
  29. Pandit, 2008, Functional analysis of sites within PCSK9 responsible for hypercholesterolemia, J. Lipid Res., 49, 1333, 10.1194/jlr.M800049-JLR200 · DOI
  30. Bourbon, 2008, Familial hypercholesterolaemia in Portugal, Atherosclerosis., 196, 633, 10.1016/j.atherosclerosis.2007.07.019 · DOI
  31. Naoumova, 2005, Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response, Arterioscler. Thromb. Vasc. Biol., 25, 2654, 10.1161/01.ATV.0000190668.94752.ab · DOI
  32. Cameron, 2008, Characterization of novel mutations in the catalytic domain of the PCSK9 gene, J. Intern. Med., 263, 420, 10.1111/j.1365-2796.2007.01915.x · DOI
  33. Homer, 2008, Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa, Atherosclerosis., 196, 659, 10.1016/j.atherosclerosis.2007.07.022 · DOI · Paper page
  34. McPherson, 2007, Statins for primary prevention of coronary artery disease, Lancet., 369, 1078, 10.1016/S0140-6736(07)60516-9 · DOI
  35. Willer, 2008, Newly identified loci that influence lipid concentrations and risk of coronary artery disease, Nat. Genet., 40, 161, 10.1038/ng.76 · DOI · Paper page
  36. Folsom, 2007, Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence, Cancer Epidemiol. Biomarkers Prev., 16, 2455, 10.1158/1055-9965.EPI-07-0502 · DOI
  37. Hooper, 2007, The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population, Atherosclerosis., 193, 445, 10.1016/j.atherosclerosis.2006.08.039 · DOI
  38. Graham, 2007, Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice, J. Lipid Res., 48, 763, 10.1194/jlr.C600025-JLR200 · DOI
  39. Frank-Kamenetsky, 2008, Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates, Proc. Natl. Acad. Sci. USA., 105, 11915, 10.1073/pnas.0805434105 · DOI
  40. Qian, 2007, Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis, J. Lipid Res., 48, 1488, 10.1194/jlr.M700071-JLR200 · DOI · Paper page
  41. Shan, 2008, PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide, Biochem. Biophys. Res. Commun., 375, 69, 10.1016/j.bbrc.2008.07.106 · DOI · Paper page
  42. Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLER* Trial), Am. J. Cardiol., 92, 152, 10.1016/S0002-9149(03)00530-7 · DOI
  43. Hallman, 2007, Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study), Am. J. Cardiol., 100, 69, 10.1016/j.amjcard.2007.02.057 · DOI
  44. Third report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002. 106: 3143–3421. · DOI · Paper page
  45. Hickman, 1998, Distributions and trends of serum lipid levels among United States children and adolescents ages 4–19 years: data from the Third National Health and Nutrition Examination Survey, Prev. Med., 27, 879, 10.1006/pmed.1998.0376 · DOI

Cited by

Sorted by citations

Metadata

Authors
Horton, J. D., Cohen, J. C., & Hobbs, H. H.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2009-04
Volume
50
Pages
S172-S177
ISSN
0022-2275
DOI
10.1194/jlr.r800091-jlr200
Cited by
533
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review